Bispecific Antibodies (BsAb) are the ultimate multitaskers in precision medicine, but creating a “Perfect Pair” requires engineering and computational foresight. Join our expert panel as we deconstruct the BsAb lifecycle from lab to clinic. We will dive into how AI is revolutionizing discovery by predicting stability, specificity, and lead viability. We’ll also share strategies for navigating manufacturing bottlenecks and overcoming development challenges. Finally, our panel will break down how to improve clinical trial design to better address BsAb efficacy and safety. 

Note: Each ticket includes light bites and beverages. Walk-ins will not be accepted.

Program

6:00 p.m. – 6:30 p.m.  Check in / Networking
6:30 p.m. – 7:30 p.m.  Panel discussion
7:30 p.m. – 8:00 p.m.  Q&A / Networking
 

Speaker Bios

Peyton Greenside, Co-Founder & CEO at BigHat Biosciences

A pioneer of deep learning applied to life science problems, Peyton has developed computational, statistical, and AI/ML techniques to model, understand, and optimize biological sequences in academia and industry. Peyton was an inaugural Schmidt Science Fellow, a computational biologist at the Broad Institute, a scientific founder of Valis, and holds a PhD from Stanford University (Accel Innovation Scholar), an MPhil in computational biology from Cambridge University (Herchel Smith Scholar), and a BA in applied math from Harvard.

Bonnie Hammer, Executive Vice President of R&D at Invenra

Bonnie has over 20 years of experience in the life science industry, having focused her career on cell biology, disease modeling, and assay development for drug discovery. She has been with Invenra since 2015, where she serves as Executive Vice President of Research & Development. Invenra is focused on the discovery and development of next-generation multi-specific antibody therapeutics with particular emphasis on oncology and immunology applications. Prior to joining Invenra, Bonnie held research & development leadership roles within Life Technologies (now Thermo Fisher Scientific), where she worked on cellular models for oncology, Parkinson’s disease, and aging, and served as a research area manager for GPCRs and ion channels. Dr. Hammer holds a PhD from the University of Oregon in biochemistry and a BS in biochemistry and molecular biology from the University of Minnesota (Duluth).

Katherine Harris, Chief Development Officer of Rondo Therapeutics

Dr. Katherine Harris is Chief Development Officer at Rondo Therapeutics, where she leads IND-enabling activities and oversees preclinical drug development from candidate nomination through IND submission. A biopharma executive and board director, she brings deep expertise in antibody therapeutics, with leadership experience spanning discovery, translational strategy, and IND development across early-stage biotech and large pharmaceutical organizations. She holds a PhD in molecular and cell biology from the University of California, Berkeley.

Seema Kantak, Senior Vice President, Head of Biologics & Biotherapeutics at Exelixis, Moderator

Seema is a biopharma executive with extensive experience in biopharma strategy leading R&D organizations. Currently, she is Senior Vice President at Exelixis, a commercial oncology company, and is responsible for future clinical candidates for Exelixis pipeline. Over her 25-year tenure in biopharma, Dr. Kantak had several roles in R&D and business strategy. She is responsible for establishing, building, and advancing a biotherapeutics portfolio at Exelixis and is leading the effort to determine development candidates consisting of antibody drug conjugates and bispecifics through a combination of internal and external innovation. She oversees strategic business alliances in biotherapeutics. Prior to joining Exelixis, Dr. Kantak consulted for venture capital, was Chief Scientific Officer at a start-up, Symic Bio, and Vice President of Research and Preclinical Development at Nektar Therapeutics, where she was responsible for global projects in oncology, inflammation, and pain, and was also a program team leader on Nektar’s NKTR-214 program. She was also Managing Director, Site Head, and Board Director of Nektar’s subsidiary in India, and was instrumental in establishing a high-performing R&D organization. Early in her career, Dr. Kantak held positions in Pharmacology and Translational Medicine at XOMA, Celera Therapeutics, and Axys Pharmaceuticals. She has served in an advisory role to biotech start-ups since 2017. Dr. Kantak has contributed to several IND submissions in multiple therapeutic areas with a focus on Oncology.

Ulrike Konrad, Vice President of Business Development at Leukocare

Ulrike is a chemist by training with an MBA and over 20 years of experience in the biopharmaceutical industry. She has built her career across the full CMC spectrum, starting in analytical characterization and quality control, where she developed deep expertise in impurity analysis and mass spectrometry, and later expanding into analytical strategy and CMC program support. Over time, her focus shifted toward drug product development, with a strong emphasis on formulation of complex biologics, including sterile injectables. Today, as VP Business Development at Leukocare AG, she combines her scientific background with a strategic perspective, working closely with biotech and pharma companies to design phase-appropriate, data-driven formulation strategies.

Katie Pfeiffer, Chief Technology Officer & Co-Founder of Infinimmune

Katie is Chief Technology Officer and co-founder of Infinimmune, a venture-backed antibody discovery company based in Alameda, CA. Infinimmune holds the world's largest database of millions of paired, antigen-specific human B cells sourced from a continuous pipeline of healthy and diseased human donors. Our platform combines wetlab innovation, computational integration, and sophisticated AI modeling to convert human evolutionary successes into breakthrough medicines. Founded in 2022, Infinimmune has advanced two candidates into clinical manufacturing and inked discovery and development partnerships with multiple pharma partners, including Merck and Immunome. Katie spent 7 years as a development and strategic leader at 10x Genomics, building innovative research tools enabling single-cell transcriptomics at massive scale. Before that, she worked in antibody development and production at Pfizer and Genentech and holds a PhD in chemical engineering from the University of California, Berkeley.

Pricing Information

• Members/Guests: $35
• Student Members/Guests: $25
• Non-members*: $65
• Student Non-members: $40

*Interested in joining Women In Bio? Click here to learn more about WIB membership and gain access to our video library, mentorship opportunities, and more. 

Please read WIB's Code of Conduct and Refund Policy.

Note: A confirmation email will be sent after registration has been completed. 

Maximum Capacity

150

Parking Information

Free parking is available on-site.

Public Transit Information

From the San Carlos Caltrain Station, walk approximately 0.5 miles to MBC BioLabs.